6-K 1 form6-k.htm

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

 

For the Month of September 2015

 

001-13248
(Commission File Number)

 

SCIVAC THERAPEUTICS INC.

(Exact name of Registrant as specified in its charter)

 

Gad Feinstein Rd.

POB 580

Rehovot, Israel 7610303

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

 

Form 20-F [X] Form 40-F [  ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____

 

 

 

 
 

 

Exhibit Index

 

Exhibit No.   Description
     
99.1   News Release dated September 21, 2015

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  SciVac Therapeutics Inc.
     
Date: September 21, 2015 By: /s/ Dr. Curtis Lockshin
    Dr. Curtis Lockshin
    Chief Executive Officer

 

3